Clinical Trial News and Research

RSS

Oral treatment of chronic hepatitis C

Valeant Pharmaceuticals today presented 24-week data from Phase 2 clinical trials of Viramidine, a nucleoside (guanosine) analog Valeant is developing in oral form for the treatment of chronic hepatitis C (HCV) in conjunction with a pegylated interferon.

17 Apr 2004

Cancer-specific protein offers new target for the development of melanoma vaccine

Scientists from the Cancer Vaccine Collaborative (CVC) have discovered that the cancer-specific protein, SSX-2, induces a spontaneous immunological reaction against cancer cells in melanoma patients, offering a new target for the development of a therapeutic melanoma vaccine. SSX-2 is the prototype of the SSX family, and is part of a larger group of proteins known as cancer/testis (CT) antigens.

16 Apr 2004

Breast cancer treatment based on MIT radar research

A breast cancer treatment based on MIT radar research that was originally aimed at detecting space-borne missiles is showing promise in the final phase of clinical testing.

16 Apr 2004

Proteomics techniques to find a possible predictor of response in a chemoprevention trial

Using new technology associated with the study of proteins, or proteomics, scientists at the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), and their colleagues have made a step toward predicting which people with familial adenomatous polyposis (FAP), an inherited condition that often leads to colon cancer, will respond to the prevention drug celecoxib.

16 Apr 2004

Liptor helps Alzheimer’s disease

In a small clinical trial enrolling 63 individuals with Alzheimer’s disease, half of those who received atorvastatin (Lipitor) stabilized or improved after one year of treatment, the trial’s principal investigator D. Larry Sparks, Ph.D., reported today at a professional meeting on Alzheimer therapy.

15 Apr 2004

FDA approves advanced malignant melanoma drug

Maxim Pharmaceuticals today announced that its treatment protocol to provide its investigational drug Ceplene(TM), in combination with interleukin-2 (IL-2), for the treatment of patients with advanced malignant melanoma, has been approved by the U.S. Food and Drug Administration (FDA).

14 Apr 2004

$Pittsburgh eye center to offer refractive procedure for presbyopia$

Pittsburgh eye center to offer refractive procedure for presbyopia

UPMC Eye Center has become one of the first in Allegheny County to offer conductive keratoplasty (CK) for presbyopia. Recently approved by the U.S. Food and Drug Administration (FDA), it is the first and only FDA-approved vision technology that improves near vision in the millions of baby boomers with presbyopia, the age-related eye condition that sets in after age 40.

14 Apr 2004

21st century is shaping up to be the "century of vaccines"

The 21st century is shaping up to be the "century of vaccines," as vaccine developers make striking progress against both emerging and longstanding diseases, according to Vaccines: Preventing Diseases and Protecting Health, from the Pan American Health Organization (PAHO).

14 Apr 2004

Study suggests ways to prevent prostate cancer

Current information on prostate cancer risk factors suggests that some cases might be prevented. One possible risk factor that can be changed is diet. You may be able to reduce your risk of prostate cancer by changing the way you eat.

11 Apr 2004

Australian research shows that ginger prevents nausea or morning sickness when pregnant

In a new push to test the validity of complementary medicines, a randomised controlled trial of ginger as a treatment for nausea and vomiting during pregnancy has found that a dose of 1.05 gm of ginger a day does help to calm nausea and vomiting.

5 Apr 2004

New center enables genetic treatments and advances

A new state-of-the-art research facility dedicated to helping produce modified cells for treatment of cancer and other diseases recently opened at the Siteman Cancer Center.

1 Apr 2004

Gene of immune system linked to severe adverse drug reaction called Stevens-Johnson syndrome (SJS)

In a study of Han Chinese patients, researchers have for the first time directly linked a gene of the immune system to a severe adverse drug reaction called Stevens-Johnson syndrome (SJS), according to a Duke University Medical Center medical geneticist and collaborators in Taiwan.

1 Apr 2004

Trial of new drug that may halt progression of Type I Diabetes

The results of a long-term clinical trial on a new drug designed to inhibit the progression of type I diabetes was announced at the International Diabetes Society meeting in Cambridge, England, March 29. The findings of the 18-month long clinical trial confirm the drug's efficacy in improving a diabetic's ability to produce insulin.

30 Mar 2004

First large-scale clinical trial of chelation therapy, a controversial treatment for heart disease

NYU Medical Center has begun enrolling patients in the first large-scale clinical trial of chelation therapy, a controversial treatment for heart disease widely practiced by complementary and alternative medicine physicians. The new, government-funded nationwide study will determine whether the therapy benefits people with coronary artery disease, the leading cause of death for both men and women in the United States.

30 Mar 2004

Enzyme called COX-2 may promote the development of ovarian tumors

Fox Chase Cancer Center scientists have identified how an enzyme called COX-2 may promote the development of ovarian tumors, adding further insight into the mechanism of COX-2 inhibitors and the prevention of this highly lethal disease. The data was presented today at the 95th Annual Meeting of the American Association for Cancer Research in Orlando, Fla.

29 Mar 2004

Growth factor protein succeeds in growing new coronary arteries

Three patients of the UC Heart & Vascular Center have grown new coronary artery branches to increase blood flow to the heart after receiving a new growth factor protein (FGF1) in November 2003. All three patients showed improved blood flow to the heart twelve weeks following the injection.

26 Mar 2004

Super glue and vascular graft surgery

Got a broken teacup, an art project, or a leaky blood vessel? “Super glue” it. Surgeons at Baylor College of Medicine in Houston are studying whether a liquid sealant, similar to common household “super glue,” forms a tight seal around blood vessels used in vascular graft surgery.

25 Mar 2004

New Research Information on Tumor Necrosis Therapy

Researchers for Peregrine Pharmaceuticals presented today at the Strategic Research Institute’s Clinical-Stage Product Partnering Summit in La Jolla, CA a summary of clinical experience with Tumor Necrosis Therapy (TNT). The TNT technology is being developed in the U.S. and Europe by Peregrine under the trade name Cotara™. Over 200 patients have been treated with TNT world-wide and a TNT product has been approved to treat grade III or IV advanced lung cancer in the People’s Republic of China. A Cotara registration study for brain cancer has been approved by the U.S. Food and Drug Administration, and a Phase I colorectal cancer study is on-going at Stanford University Medical Center.

25 Mar 2004

Indiplon may help insomniacs improve their quality of sleep

Neurocrine Biosciences, Inc. has announced a second long term Phase III trial with highly positive efficacy results from its three month pivotal study, referred to as "SLEEP," the Study of Long-term Efficacy and Safety of indiplon modified release in Primary (Chronic) Insomnia patients.

24 Mar 2004

£5m for HIV/AIDS trial involving HIV patients in London, Moscow, South Africa and Australia

A joint Oxford University/Imperial College research programme into HIV/AIDS has received £5 million support from the Wellcome Trust to carry out a drug trial involving HIV patients in London, Moscow, South Africa and Australia.

24 Mar 2004

Clinical Trial News and Research

Oral treatment of chronic hepatitis C

Cancer-specific protein offers new target for the development of melanoma vaccine

Breast cancer treatment based on MIT radar research

Proteomics techniques to find a possible predictor of response in a chemoprevention trial

Liptor helps Alzheimer’s disease

FDA approves advanced malignant melanoma drug

Pittsburgh eye center to offer refractive procedure for presbyopia

21st century is shaping up to be the "century of vaccines"

Study suggests ways to prevent prostate cancer

Australian research shows that ginger prevents nausea or morning sickness when pregnant

New center enables genetic treatments and advances

Gene of immune system linked to severe adverse drug reaction called Stevens-Johnson syndrome (SJS)

Trial of new drug that may halt progression of Type I Diabetes

First large-scale clinical trial of chelation therapy, a controversial treatment for heart disease

Enzyme called COX-2 may promote the development of ovarian tumors

Growth factor protein succeeds in growing new coronary arteries

Super glue and vascular graft surgery

New Research Information on Tumor Necrosis Therapy

Indiplon may help insomniacs improve their quality of sleep

£5m for HIV/AIDS trial involving HIV patients in London, Moscow, South Africa and Australia

eBook: Using iPSCs models for human disease research and drug discovery eBook

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Latest Life Science News